[Therapeutic effectiveness of ceftizoxime on severe infections associated with hematologic disorders]

• Abstract: One hundred patients with severe infections associated with hematologic disorders, including leukemia and lymphoma, were treated with ceftizoxime (CZX) in daily doses of 4 approximately 9 g for an average of 8.9 days. In the 84 patients who completed the trial, response was excellent in 27 (32.1%) and moderate in 25 (29.8%). The rate of effectiveness was 61.9%. The only side effect seen during the treatment was skin rash in 3 patients. Hepatic disorders were observed in 5 patients. The relation between CZX and these abnormal findings was not established. These results indicate that CZX is a therapeutically effective and safe antibiotic for the treatment of severe infections in patients with underlying hematologic disorders.
• Authors: A Kanamaru, K Nagai, T Masaoka, H Shibata, T Kitani, N Taniguchi, A Horiuchi, H Hasegawa, H Kawagoe, M Hirata
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 37 Issue 1 Pg. 136-44 (Jan 1984) ISSN: 0368-2781 [Print] JAPAN
• PMID: 6328059 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Cefotaxime
• Ceftizoxime

Topics

• Adolescent
• Adult
• Aged
• Bacterial Infections (drug therapy, etiology)
• Cefotaxime (analogs & derivatives, therapeutic use)
• Ceftizoxime
• Child
• Drug Evaluation
• Female
• Hematologic Diseases (complications)
• Humans
• Male
• Middle Aged